stockmarketproxy
/
TEVANYSE,OTC SEC EDGAR

TEVA PHARMACEUTICAL INDUSTRIES LTD

Pharmaceutical Preparations·TEL AVIV·FY end 12/31·CIK 818686
OverviewFinancialsCompensationGovernanceInsidersFilings

Financials

5-year history · USD
MetricFY 2025FY 2024FY 2023FY 2022FY 2021Trend
Revenue$1.5B$16.5B$15.8B$14.9B$15.9B
Gross Profit$8.9B$8.1B$7.6B$7.0B$7.6B
Operating Income$2.2B-$303.0M$344.0M-$2.1B$1.7B
Net Income$1.4B-$1.6B$70.0M-$2.4B$417.0M
Operating CF$1.6B$1.2B$1.4B$1.6B$798.0M
Capex———$548.0M$562.0M
Free Cash Flow———$1.0B$236.0M
Buybacks——————
Dividends——————
Gross Margin595.9%48.7%48.2%46.7%47.8%
Operating Margin143.8%-1.8%2.2%-14.1%10.8%
Net Margin94.0%-9.9%0.4%-15.8%2.6%
FCF Margin———7.0%1.5%
R&D / Revenue———0.7%——
Effective Tax——————
Debt / Equity——————
Buybacks / FCF——————

Peer comparison

Pharmaceutical Preparations · 5 peers
CEO Pay Ratio
TEVA
257:1
ROIV
518:1
AXSM
23:1
COGT
95:1
PFE
277:1
ABT
166:1
CEO total comp
TEVA
$19M
ROIV
$163M
AXSM
$34M
COGT
$28M
PFE
$28M
ABT
$24M
Net Margin
TEVA
94.0%
ROIV
-592.0%
AXSM
-28.7%
COGT
—
PFE
12.4%
ABT
14.7%